CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update CytoSorbents files for FDA De Novo marketing approval of DrugSorb-ATR to reduce the severity of CABG-related bleeding due to the blood thinner ticagrelor

Multiple Factors Influence Five-Year Survival After Angioplasty, Bypass Procedures FRIDAY NEWS TIP Embargoed for 9 a.m. ET ATLANTA, May 11, 2012 (GLOBE NEWSWIRE) --The effectiveness of heart bypass grafts and angioplasty procedures on five-year survival varies significantly...